There is no single FDA-approved injection that cures nicotine addiction, despite what some clinic advertisements suggest. Several injection-based approaches to smoking cessation do exist or are in development, ranging from anticholinergic “quit smoking shots” offered at private clinics to experimental nicotine vaccines tested in clinical trials. Their track records vary widely, and the science behind each is quite different. Understanding what these shots actually do, and how well they work, can help you separate genuinely promising research from marketing hype.
The Anticholinergic “Quit Smoking Shot”
If you search online for a shot to quit smoking, you will likely come across private clinics offering an injection of anticholinergic drugs, sometimes marketed under brand names like Welplex or similar. The protocol typically involves a subcutaneous injection of atropine, scopolamine, and chlorpromazine, followed by a two-week course of oral medications and periodic follow-up visits over the next year.1PubMed. The use of anticholinergic drugs for smoking cessation: a pilot study The idea is that these drugs block certain nerve signals associated with nicotine withdrawal, easing the physical discomfort of quitting.
Clinics offering this treatment sometimes cite impressive numbers. One retrospective study from a clinic network reported that about 78% of patients remained smoke-free at 60 days and 56% stayed abstinent through a full year. Those figures sound remarkable, but context matters. The study was self-reported, conducted by the clinics themselves, and was not a randomized controlled trial with a placebo group. Independent, peer-reviewed research on this specific protocol is extremely thin. The original pilot study from the 1980s described the approach as showing “promise,” but large-scale, rigorous trials have never been published.
Safety is another concern. Anticholinergic drugs can cause serious side effects, particularly in older adults or people with underlying health conditions. One published case report described a 61-year-old man who developed visual and auditory hallucinations after receiving scopolamine and atropine at a smoking cessation clinic and ended up in the emergency department.2Journal of Pharmacy Practice. Psychosis From Anticholinergic Medications Administered at a Smoking Cessation Clinic These drugs affect the central nervous system broadly, and the risk of confusion, dry mouth, blurred vision, rapid heartbeat, and in rare cases psychosis is well documented. Most major medical organizations have not endorsed this approach, and it is not covered by insurance.
Nicotine Vaccines and How They Work
A fundamentally different kind of “shot to quit smoking” is the nicotine vaccine, which works more like a traditional vaccine than a drug injection. Instead of blocking withdrawal symptoms, a nicotine vaccine trains your immune system to produce antibodies that bind to nicotine molecules in the bloodstream. Once nicotine is bound to an antibody, the resulting complex is too large to cross the blood-brain barrier, so the nicotine never reaches the brain’s reward centers.3CNS & Neurological Disorders – Drug Targets. Nicotine Vaccines Without the dopamine surge that nicotine normally triggers, smoking becomes less satisfying, and the motivation to keep doing it fades.
Animal studies confirmed the basic concept works in principle. Rats immunized against nicotine showed a suppressed dopamine response in the brain region most associated with reward and addiction, essentially blunting the “feel-good” effect that keeps smokers hooked.4Karger. Active Immunization against Nicotine Suppresses Nicotine-Induced Dopamine Release in the Rat Nucleus accumbens Shell Because the vaccine acts on the drug in the bloodstream rather than on brain receptors, it avoids the kind of neurological side effects that come with drugs acting directly on the central nervous system.5PubMed Central. Targeting nicotine addiction: the possibility of a therapeutic vaccine
Why First-Generation Nicotine Vaccines Failed in Trials
The most advanced nicotine vaccine to reach large human trials was NicVAX, developed by Nabi Biopharmaceuticals. Early results looked encouraging: in a Phase IIb trial, smokers who developed high levels of anti-nicotine antibodies had a significantly higher quit rate than those on placebo.6BioSpace. Nabi Biopharmaceuticals Shares Rise on Positive Results of Phase IIb Trial of NicVAX The catch was that only a subset of vaccinated participants produced enough antibodies to make a difference. For those with a weaker immune response, the vaccine was no better than a placebo.
This problem proved fatal to NicVAX’s prospects. Two large Phase III trials, each enrolling roughly a thousand smokers who received six injections of the vaccine, failed to meet their primary endpoint. There was no statistically significant difference in long-term abstinence between the vaccinated group and the placebo group overall.7PubMed Central. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial The vaccine concept was sound, but the delivery technology could not reliably generate strong enough antibody levels across a diverse population. NicVAX development was effectively shelved after those results.
Next-Generation Nanovaccines
Researchers have not abandoned the nicotine vaccine idea. Instead, they shifted focus to improving how the nicotine molecule is presented to the immune system. The weakness of first-generation vaccines like NicVAX was their reliance on traditional protein carriers that produced inconsistent immune responses. Newer approaches use engineered nanoparticles to deliver the nicotine-mimicking molecule (called a hapten) more efficiently to immune cells.
One line of research uses hybrid nanoparticles that are taken up by dendritic cells, the immune system’s “alarm cells,” more efficiently than older conjugate vaccines. In mouse studies, these nanovaccines generated significantly stronger antibody responses at comparable doses and kept more nicotine in the bloodstream and out of the brain.8PubMed Central. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density The density of hapten molecules on the nanoparticle surface turned out to be a key factor: packing more of them on produced stronger and more targeted immune responses.
Other teams have experimented with liposome-based delivery systems and carbon nanohorn scaffolds. A liposome-protein nanoparticle vaccine produced antibody levels several times higher than conventional conjugate vaccines in mice.9PubMed Central. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle A separate approach built on negatively charged carbon nanohorns supporting cationic liposomes also induced high-titer, high-affinity anti-nicotine antibodies in animal models.10Journal of Biomedical Nanotechnology. Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine Hapten design also matters: researchers found that specific hapten structures conjugated to certain carrier proteins could retain over twice as much nicotine in the blood and reduce nicotine reaching the brain by up to 60% compared to unvaccinated controls.11PLOS ONE. Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice
All of this work remains preclinical, meaning it has been tested in animals but not yet in large human trials. The jump from mouse to human is steep in immunology, and there is no guarantee these improved platforms will solve the consistency problem that sank NicVAX. Still, the improvements in antibody response are substantial enough that several groups continue to pursue human trials.
Passive Immunization With Monoclonal Antibodies
Instead of training your body to make its own anti-nicotine antibodies through vaccination, passive immunization skips that step entirely by injecting pre-made monoclonal antibodies directly into the bloodstream. The advantage is predictability: every patient gets the same dose of antibodies, eliminating the problem of inconsistent immune responses that derailed NicVAX.
The disadvantage is practical. Monoclonal antibodies are expensive to manufacture and have a shorter half-life in the body than antibodies your own immune system produces, meaning repeated injections would be needed. One approach being studied combines both strategies: vaccinate the patient to build up a baseline antibody level, then supplement with targeted monoclonal antibody injections to boost protection at critical moments. In animal studies, this combination completely blocked the behavioral effects of nicotine, while vaccination alone or antibody infusion alone was only minimally effective.12PubMed. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy This hybrid approach could reduce the cost barrier by limiting how much monoclonal antibody is needed.
Injectable Depot Therapies for Smoking Cessation
A different angle on the “shot to quit smoking” involves long-acting injectable formulations of drugs already known to help with cessation. The concept borrows from how medications like long-acting injectable naltrexone work for alcohol and opioid use disorders: a single injection slowly releases the drug over weeks, removing the need for daily pills and the risk of forgetting doses.
An interesting incidental finding involves injectable extended-release naltrexone, which is FDA-approved for opioid and alcohol addiction. Researchers noticed that patients receiving monthly naltrexone injections for opioid use disorder also cut their cigarette consumption, dropping from about 14 cigarettes per day to under 9 within two months.13PubMed. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder Naltrexone blocks opioid receptors, which play a secondary role in nicotine’s reward pathway. The reduction was not the drug’s intended purpose, but the effect was consistent enough to warrant further study.
On the nicotine replacement side, researchers have developed injectable gel formulations designed to release nicotine steadily over several days from a single shot. One experimental system used temperature-sensitive polymers that are liquid at room temperature but form a gel depot under the skin at body temperature, sustaining nicotine release for about five days in laboratory testing.14PubMed Central. Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation This could replace daily patches or gum for people who struggle with compliance, though the formulation has not yet been tested in humans. The broader field of sustained-release drug delivery is actively exploring implants and injectable systems for addiction treatment.15PubMed. Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review
How Available Treatments Compare
While most injection-based approaches are still experimental, the question of how they stack up against proven treatments is worth addressing. The two most effective pharmacological treatments with strong evidence behind them are varenicline (sold as Chantix or Champix) and combination nicotine replacement therapy, both of which are taken orally or via patches and gum rather than by injection. A large study tracking over 220,000 patients in primary care found that roughly 29% of those prescribed varenicline were still not smoking at two years, compared with about 24% of those on nicotine replacement therapy.16PubMed Central. The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records Those numbers provide a useful benchmark for evaluating any new injection-based therapy.
For smokers who fail an initial quit attempt, switching strategies can help. A randomized trial found that smokers who had not quit after six weeks on nicotine replacement therapy benefited from switching to varenicline, with roughly a 6-percentage-point improvement in their chances of being smoke-free at twelve weeks compared to continuing the same regimen.17JAMA. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial The point is that even with current medications, quit rates are modest, and many smokers need multiple attempts. An effective vaccine or injectable therapy that could maintain steady drug levels or permanently alter how the brain responds to nicotine would fill a genuine gap.
Cost and Access Considerations
The anticholinergic clinic shots typically cost several hundred to over a thousand dollars out of pocket, since insurance does not cover them. If the nanovaccine approach eventually makes it to market, pricing is unknown but likely to be significant given the complexity of nanoparticle manufacturing. Monoclonal antibody therapies are among the most expensive drug classes in medicine, which is why researchers are working to minimize the dose needed through combination strategies.
For comparison, standard cessation aids vary widely in cost. Cytisine, a plant-based drug used for decades in Eastern Europe and recently gaining regulatory attention elsewhere, is several times cheaper than varenicline per treatment course and has been found to be significantly more cost-effective, even though it appears somewhat less clinically effective.18Tobacco Prevention and Cessation. On cytisine’s safety, efficacy and cost-effectiveness in smoking cessation: A brief summary of clinical and pharmacoeconomic study results Extended pharmacotherapy with varenicline has been modeled at roughly $6,300 per quality-adjusted life year gained in older smokers, which is considered highly cost-effective by standard health-economic thresholds.19PubMed Central. Cost-effectiveness of Extended Cessation Treatment for Older Smokers Any injectable therapy entering the market would need to demonstrate value against these benchmarks to gain traction with insurers and health systems.
Who Should Be Cautious
Certain groups face additional considerations when it comes to injectable cessation treatments. For pregnant women, the standard recommendation is behavioral counseling and support rather than medication, because the safety of pharmacological treatments during pregnancy has not been firmly established.20PubMed Central. Smoking Cessation Strategies Targeting Specific Populations This applies doubly to experimental injections with limited safety data. Adolescents are generally steered toward counseling first, with nicotine replacement used cautiously only in cases of serious dependence.
Older adults and people with cardiovascular disease, glaucoma, or urinary retention face heightened risks from anticholinergic drugs specifically, since those medications can worsen all of these conditions. Anyone considering a clinic-based “quit smoking shot” should ask exactly what drugs are in the injection, whether the clinic has a physician on site, and what peer-reviewed evidence supports the specific protocol being offered. The honest answer from most independent experts is that the evidence base is too thin to recommend anticholinergic shots over established treatments.
The Psychology of the “One Shot” Promise
Part of the appeal of a quit-smoking shot is psychological. The idea of a single decisive act, walking into a clinic, getting an injection, and walking out a non-smoker, is powerfully attractive to people who have struggled through patches that fall off, gum that tastes terrible, and pills that need to be taken for months. Research into public attitudes toward cessation treatment has found that while pharmacological aids are the most commonly mentioned method for quitting, most people recognize that medication alone is not enough. Common themes in interviews with smokers, ex-smokers, and nonsmokers include the belief that a person has to “really want to quit” and that the best treatment depends on the individual.21Oxford Academic (Nicotine & Tobacco Research). Public Attitudes Toward the Treatment of Nicotine Addiction
That instinct is backed by evidence. Nicotine addiction involves both a physical dependence on the drug and deeply ingrained behavioral habits: smoking with coffee, smoking after meals, smoking during stress. No injection addresses the behavioral component. Even the most effective future vaccine would need to be paired with some form of behavioral support to help smokers navigate the triggers and routines that keep them reaching for cigarettes long after the chemical craving has been addressed. Clinics that sell a shot as a standalone miracle cure are oversimplifying a complex problem, however appealing the simplicity might be.
Where Things Stand Today
If you are a smoker looking for an injection-based quit aid right now, your options are limited and mostly unproven. The anticholinergic shots available at private clinics lack strong independent evidence and carry real risks. Nicotine vaccines showed conceptual promise but failed in large trials due to inconsistent antibody responses. Next-generation nanovaccines are producing exciting results in animal models but are years away from being available to patients. Long-acting injectable formulations of existing cessation drugs are in early development. The incidental finding that injectable naltrexone reduces smoking in people being treated for opioid addiction is intriguing but has not been pursued specifically as a smoking cessation strategy in its own right.
The field is genuinely active. Nanoparticle delivery, hapten optimization, and combination immunotherapy strategies represent serious scientific efforts that could eventually produce a vaccine or injectable treatment that works reliably in humans. For now, though, the treatments with the strongest evidence behind them are oral varenicline, nicotine replacement therapy in various forms, and behavioral counseling. If a clinic promises you a shot that will end your addiction in a single visit, that claim is running well ahead of the science.